Back to search

Article

Clinical validation of an RSV neutralization assay and testing of cross-sectional sera pre- and post- RSV outbreaks from 2021-2023

2024-06-14

Abstract excerpt

<h4>Background</h4> Respiratory syncytial virus (RSV) is a leading cause of acute respiratory infections and hospitalization in infants and the elderly. Newly approved vaccines and the prophylactic antibody nirsevimab have heightened interest in RSV immunologic surveillance, necessitating development of high-throughput assays assessing anti-RSV neutralizing activity. <h4>Objectives</h4> We validated an RSV focus-r...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
f316d02f-709e-5344-b313-936ce9dddd18
DOI
10.1101/2024.06.13.24308891
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Clinical validation of an RSV neutralization assay and testing of cross-sectional sera pre- and post- RSV outbreaks from 2021-2023DOI 10.1101/2024.06.13.24308891
Genomic and Immunological Characterisation Shows Increased Respiratory Syncytial Virus Cases Not Due to Waning Antibody Mediated ImmunitySemantic proximity
Development and Validation of Novel Cell-free Direct Neutralization Assay for SARS-CoV-2Semantic proximity
Estimated SARS-CoV-2 Antibody Seroprevalence and Infection to Case Ratio Trends in 50 States and District of Columbia, United States—October 25, 2020, to February 26, 2022Semantic proximity
Clinical, Genomic, and Immunological Characterization of RSV Surge in Sydney, Australia, 2022Semantic proximity
Subtype-specific differences in susceptibility to monoclonal antibodies and vaccines among contemporary RSV-A and RSV-B isolatesSemantic proximity
Genomic Surveillance and Antigenic Characterization of Respiratory Syncytial Virus (RSV) in Spain During the 2023-2024 Season of Nirsevimab Administration.Semantic proximity
IMMUNO-COV™ v2.0: Development and Validation of a High-Throughput Clinical Assay for Measuring SARS-CoV-2-Neutralizing Antibody TitersSemantic proximity
Respiratory syncytial virus infection and reinfection patterns during a community outbreak in Kenya investigated by whole genome sequencing, 2023/2024Semantic proximity
Resurgence of respiratory syncytial virus with dominance of RSV-B during the 2022–2023 seasonSemantic proximity
Respiratory syncytial virus surge in 2022 caused by lineages already present before the COVID‐19 pandemicSemantic proximity
Bivalent RSVpreF effectiveness against RSV-related lower respiratory tract disease hospitalization and ED visits across three RSV SeasonsSemantic proximity
Reduced control of SARS-CoV-2 infection is associated with lower mucosal antibody responses in pregnant womenSemantic proximity
Select a neighboring publication to make it the new centre.